top of page
  • Safi Bello

Allergan chops 1,400 jobs to cope with early Restasis generics

Fierce Pharma --------- Back in November, as Allergan was reeling from the news that it could face earlier-than-expected copies of its blockbuster eye drug Restasis, CEO Brent Saunders promised investors that cost cuts were coming “rapidly.”Just over two months later, they’re here. The company is letting go more than 1,000 staffers across its commercial team and other areas, it said in a Wednesday financial filing. It’s also axing about 400 jobs that aren’t currently filled, for a total job-cutting toll of 1,400. Allergan also plans to squeeze out additional savings through non-headcount related measures—though it didn’t say what those measures were, or how much they would save. To learn more click on the picture below to read the article.

Allergan chops 1,400 jobs to cope with early Restasis generics - Read More from Fierce Pharma

2 views
Featured Posts
Recent Posts
Follow Us
  • Instagram
  • Pinterest
  • Tumblr Social Icon
bottom of page